Mesoblast (ASX:MSB) reported Friday fiscal first-half loss of $0.0311 per share, compared with $0.042 a year earlier.

Revenue for the six months ended Dec. 31, 2025, was $51.3 million, compared with $3.2 million a year earlier. Analysts surveyed by FactSet expected $53.1 million.

The company said it expects fiscal 2026 net revenue of Ryoncil, the company's mesenchymal stromal cell therapy, to range between $110 million and $120 million.